TY - JOUR
T1 - SARS-CoV-2 Infection Leads to Neurological Dysfunction
AU - Acharya, Arpan
AU - Kevadiya, Bhavesh D.
AU - Gendelman, Howard E.
AU - Byrareddy, Siddappa N.
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - A number of neurological disease complications have been seen following infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most person with COVID-19 respiratory disease demonstrate headache, nausea and vomiting, up to 40% present also experience dizziness, confusion, cerebrovascular disease, muscle pain, ataxia and seizures. Loss of taste and smell, defects in visual acuity and pain occur in parallel. Such central nervous system (CNS) signs and symptoms linked to laboratory-confirmed SARS-CoV-2 infection is often life threatening. Health care providers currently evaluating patients with neurologic symptoms need consider COVID-19 in any differential diagnosis. These considerations will facilitate prompt testing, isolation and prevention of viral transmission speeding best clinical outcomes. [Figure not available: see fulltext.].
AB - A number of neurological disease complications have been seen following infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most person with COVID-19 respiratory disease demonstrate headache, nausea and vomiting, up to 40% present also experience dizziness, confusion, cerebrovascular disease, muscle pain, ataxia and seizures. Loss of taste and smell, defects in visual acuity and pain occur in parallel. Such central nervous system (CNS) signs and symptoms linked to laboratory-confirmed SARS-CoV-2 infection is often life threatening. Health care providers currently evaluating patients with neurologic symptoms need consider COVID-19 in any differential diagnosis. These considerations will facilitate prompt testing, isolation and prevention of viral transmission speeding best clinical outcomes. [Figure not available: see fulltext.].
KW - Animal models
KW - CNS
KW - COVID-19
KW - Guillain-Barré syndrome
KW - Neurologic manifestations
KW - SARS-CoV-2
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85085285043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085285043&partnerID=8YFLogxK
U2 - 10.1007/s11481-020-09924-9
DO - 10.1007/s11481-020-09924-9
M3 - Article
C2 - 32447746
AN - SCOPUS:85085285043
VL - 15
SP - 167
EP - 173
JO - Journal of NeuroImmune Pharmacology
JF - Journal of NeuroImmune Pharmacology
SN - 1557-1890
IS - 2
ER -